Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Smoking-Related Lung Cancer Remains Elevated 25 Years After Quitting

June 9, 2018
By Dave Levitan
Article

Among former heavy smokers, the risk for lung cancer remains significantly increased compared with never-smokers, even more than 25 years since quitting.

Among former heavy smokers, the risk for lung cancer remains significantly increased compared with never-smokers, even more than 25 years since quitting (YSQ), according to an analysis from the Framingham Heart Study.

“Guidelines adopted by the Centers for Medicare and Medicaid Services (CMS) mandate insurance coverage of low-dose computed tomography (LDCT) screening for current or former smokers who meet age and pack-year criteria, but they exclude former smokers with more than 15 YSQ,” wrote study authors led by Hilary A. Tindle, MD, MPH, of Vanderbilt University Medical Center in Nashville. “If the risk of lung cancer in fact remains elevated for more than 15 YSQ, then extending the screening window in former smokers could augment early detection without diminishing screening effectiveness.”

The investigators used data from the Framingham Heart Study to study this question, including 3,905 individuals from the original cohort and 5,002 from the offspring cohort. The median follow-up period was 28.7 years; results were published in the Journal of the National Cancer Institute.

During the follow-up period, a total of 284 lung cancers were found. In current smokers, the incidence rate for lung cancer was 1.97 per 1,000 person-years; in former smokers, that rate was 1.61/1,000 person-years, and in never-smokers, it was 0.26/1,000 person-years.

When compared with never-smokers, former heavy smokers (those with at least 21.3 cumulative pack-years of smoking history) had a significantly higher risk of lung cancer at all time points, though this did diminish over time. At < 5 YSQ, the adjusted hazard ratio (HR) for lung cancer in former heavy smokers was 12.12 (95% CI, 6.94–21.17; P < .001).

From 5 to < 10 YSQ, the HR was 11.77 (95% CI, 6.78–20.45; P < .001), and from 10 to < 15 YSQ, it was 7.81 (95% CI, 3.98–15.33; P < .001). From 15 to < 25 YSQ, the risk dropped further but was still significantly higher, with an HR of 5.88 (95% CI, 3.19–10.83; P < .001). And at more than 25 YSQ, the risk was still significant, with an HR of 3.85 (95% CI, 1.80–8.26; P < .001).

“The importance of smoking cessation cannot be overstated,” the authors wrote. “Persistently elevated lung cancer risk in former smokers is important, given that 4 of every 10 lung cancers diagnosed in former smokers occur in people with more than 15 YSQ, who are beyond the current window of eligibility for lung cancer screening.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

ONCOLOGY Staff
June 20th 2025
Article

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.


Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff
June 19th 2025
Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Related Content

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

Treatment Options and AE Considerations in First-Line EGFR+ NSCLC

ONCOLOGY Staff
June 20th 2025
Article

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.


Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients

ONCOLOGY Staff
June 19th 2025
Article

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.